Add to ORKGPlasma cell leukemia represents the most aggressive form of plasma cell dyscrasia. We report a 67-year old male with no previous medical illnesses presented with anemic symptoms. Blood film revealed 35% circulating plasma cells, bone marrow biopsy showed plasma cells constituting 85%. Diagnosis of primary plasma cell leukemia was completed. Induction chemotherapy with bortezomib, doxorubicin, and dexamethasone was started. After the first cycle, plasma cells in peripheral blood disappeared. The patient had complete remission at evaluation after the third cycle. Re-evaluation after the sixth cycle showed that he maintained remission. As he was non-transplant eligible, he was we kept on maintenance bortezomib. Twenty-four months after the dia...
International audiencePURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignan...
Primary Plasma cell leukaemia (pPCL) is a rare plasma cell (PC) malignancy. The strict criteria for ...
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered ...
Background: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a var...
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plas...
Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise eit...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezo...
AbstractPlasma cell leukaemia (PCL) is a rare and aggressive disease. Diagnosis is made when there a...
Plasma cell leukemia (PCL) is a rare form of malignant plasma cell dyscrasia. It can occur as a prim...
BACKGROUND: The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown ...
Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed mul...
Plasma cell leukemia (PCL) is a rare form of plasma cell dyscrasia. Between 2% and 4% of malignant P...
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasias that can occur...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
Background: Epidemiological and clinical information on primary plasma cell leukemia (pPCL) are rare...
International audiencePURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignan...
Primary Plasma cell leukaemia (pPCL) is a rare plasma cell (PC) malignancy. The strict criteria for ...
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered ...
Background: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a var...
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plas...
Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise eit...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezo...
AbstractPlasma cell leukaemia (PCL) is a rare and aggressive disease. Diagnosis is made when there a...
Plasma cell leukemia (PCL) is a rare form of malignant plasma cell dyscrasia. It can occur as a prim...
BACKGROUND: The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown ...
Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed mul...
Plasma cell leukemia (PCL) is a rare form of plasma cell dyscrasia. Between 2% and 4% of malignant P...
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasias that can occur...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
Background: Epidemiological and clinical information on primary plasma cell leukemia (pPCL) are rare...
International audiencePURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignan...
Primary Plasma cell leukaemia (pPCL) is a rare plasma cell (PC) malignancy. The strict criteria for ...
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered ...